文献速递心脑血管急症重症综合管理与镇静镇痛

2000-18年美国和加拿大年龄-性别特异性肺栓塞相关死亡率:WHO死亡数据库与CDC多死因数据库分析

Age-sex specific pulmonary embolism-related mortality in the USA and Canada, 2000-18: an analysis of the WHO Mortality Database and of the CDC Multiple Cause of Death database.
PubMed 文献 · Lancet Respir Med · 2020-10-12

这项回顾性流行病学研究利用WHO死亡数据库(美国、加拿大2000-17年)和CDC多死因数据库(美国2000-18年),分析肺栓塞相关死亡率的时间趋势、死亡证明上报告的 contributing conditions 以及年龄性别分布,并针对美国进行种族亚组分析。25-64岁成人2006年后上升。PE死亡中位年龄从73岁降至68岁(2000-18)。

要点

  • 美国25-64岁成人PE相关死亡率2006年后上升;PE死亡中位年龄从73岁降至68岁(2000-18)。
  • 美国黑人PE年龄标化死亡率持续比白人高至多50%,白人又比其他种族约高50%。
  • 美国2000-2018年所有年龄组中,癌症、呼吸系统疾病和感染作为PE相关死亡 contributing cause 的患病率均增加。

适用人群与场景

  • 美国(2000-18年)和加拿大(2000-17年)经医学认证的死亡登记数据,涵盖全人群;美国亚组分析按种族进行。
  • 原文未提及急诊、ICU或院前场景的纳入排除标准。

诊断标准与关键阈值

  • 原文未提及

处置流程与药物剂量

  • 原文未提及

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 研究类型:回顾性流行病学研究;数据来源:WHO死亡数据库(美国、加拿大2000-17年)和CDC多死因数据库(美国2000-18年);样本量原文未提及。
  • 美国25-64岁成人PE相关死亡率2006年后上升;PE死亡中位年龄从73岁降至68岁(2000-18)。
  • 美国2000-2018年所有年龄组中,癌症、呼吸系统疾病和感染作为PE相关死亡 contributing cause 的患病率增加。
  • 美国黑人PE年龄标化死亡率持续比白人高至多50%;白人又比其他种族约高50%。

证据类型、等级与局限

  • 证据类型:回顾性流行病学研究(基于死亡登记数据库)。
  • 局限:原文未述局限性。

对床旁实践的改变

  • 原文提示美国25-64岁成人PE相关死亡率2006年后上升,临床需关注该年龄段人群的PE风险。
  • 原文提示美国PE死亡中位年龄下降(73岁降至68岁),癌症、呼吸系统疾病和感染作为 contributing cause 的患病率增加。
  • 原文提示美国黑人PE年龄标化死亡率持续高于白人,白人又高于其他种族,存在种族差异。
  • 原文观察性数据不能推断因果,不能据此改变具体诊治方案。

指南或共识出处

  • Lancet Respir Med;原文未提及具体指南或共识名称。

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

BACKGROUND: Pulmonary embolism (PE)-related mortality is decreasing in Europe. However, time trends in the USA and Canada remain uncertain because the most recent analyses of PE-related mortality were published in the early 2000s.

METHODS: For this retrospective epidemiological study, we accessed medically certified vital registration data from the WHO Mortality Database (USA and Canada, 2000-17) and the Multiple Cause of Death database produced by the Division of Vital Statistics of the US Centers for Disease Control and Prevention (CDC; US, 2000-18). We investigated contemporary time trends in PE-related mortality in the USA and Canada and the prevalence of conditions contributing to PE-related mortality reported on the death certificates. We also estimated PE-related mortality by age group and sex. A subgroup analysis by race was performed for the USA.

FINDINGS: In the USA, the age-standardised annual mortality rate (PE as the underlying cause) decreased from 6·0 deaths per 100 000 population (95% CI 5·9-6·1) in 2000 to 4·4 deaths per 100 000 population (4·3-4·5) in 2006. Thereafter, it continued to decrease to 4·1 deaths per 100 000 population (4·0-4·2) in women in 2017 and plateaued at 4·5 deaths per 100 000 population (4·4-4·7) in men in 2017. Among adults aged 25-64 years, it increased after 2006. The median age at death from PE decreased from 73 years to 68 years (2000-18). The prevalence of cancer, respiratory diseases, and infections as a contributing cause of PE-related death increased in all age categories from 2000 to 2018. The annual age-standardised PE-related mortality was consistently higher by up to 50% in Black individuals than in White individuals; these rates were approximately 50% higher in White individuals than in those of other races. In Canada, the annual age-standardised mortality rate from PE as the underlying cause of death decreased from 4·7 deaths per 100 000 population (4·4-5·0) in 2000 to 2·6 deaths per 100 000 population (2·4-2·8) in 2017; this decline slowed after 2006 across age groups and sexes.

INTERPRETATION: After 2006, the initially decreasing PE-related mortality rates in North America progressively reached a plateau in Canada, while a rebound increase was observed among young and middle-aged adults in the USA. These findings parallel recent upward trends in mortality from other cardiovascular diseases and might reflect increasing inequalities in the exposure to risk factors and access to health care.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

参考来源

  1. Barco S, Valerio L, Ageno W, et al. Age-sex specific pulmonary embolism-related mortality in the USA and Canada, 2000-18: an analysis of the WHO Mortality Database and of the CDC Multiple Cause of Death database. Lancet Respir Med. 2020. PMID: 33058771. doi:10.1016/S2213-2600(20)30417-3

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。